92 related articles for article (PubMed ID: 25033953)
1. Tetranectin knockout mice develop features of Parkinson disease.
Wang ES; Zhang XP; Yao HB; Wang G; Chen SW; Gao WW; Yao HJ; Sun YR; Xi CH; Ji YD
Cell Physiol Biochem; 2014; 34(2):277-87. PubMed ID: 25033953
[TBL] [Abstract][Full Text] [Related]
2. Dopamine D2 receptor knockout mice develop features of Parkinson disease.
Tinsley RB; Bye CR; Parish CL; Tziotis-Vais A; George S; Culvenor JG; Li QX; Masters CL; Finkelstein DI; Horne MK
Ann Neurol; 2009 Oct; 66(4):472-84. PubMed ID: 19847912
[TBL] [Abstract][Full Text] [Related]
3. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
4. Alpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease.
Frahm S; Melis V; Horsley D; Rickard JE; Riedel G; Fadda P; Scherma M; Harrington CR; Wischik CM; Theuring F; Schwab K
Behav Brain Res; 2018 Feb; 339():153-168. PubMed ID: 29180135
[TBL] [Abstract][Full Text] [Related]
5. Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys.
Recasens A; Dehay B; Bové J; Carballo-Carbajal I; Dovero S; Pérez-Villalba A; Fernagut PO; Blesa J; Parent A; Perier C; Fariñas I; Obeso JA; Bezard E; Vila M
Ann Neurol; 2014 Mar; 75(3):351-62. PubMed ID: 24243558
[TBL] [Abstract][Full Text] [Related]
6. How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?
Volpicelli-Daley LA; Kirik D; Stoyka LE; Standaert DG; Harms AS
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl 1):131-155. PubMed ID: 27018978
[TBL] [Abstract][Full Text] [Related]
7. Exogenous Tetranectin Alleviates Pre-formed-fibrils-induced Synucleinopathies in SH-SY5Y Cells by Activating the Plasminogen Activation System.
Lin H; Tang R; Fan L; Wang E
Neurochem Res; 2022 Oct; 47(10):3192-3201. PubMed ID: 35895152
[TBL] [Abstract][Full Text] [Related]
8. Glucocerebrosidase deficiency in dopaminergic neurons induces microglial activation without neurodegeneration.
Soria FN; Engeln M; Martinez-Vicente M; Glangetas C; López-González MJ; Dovero S; Dehay B; Normand E; Vila M; Favereaux A; Georges F; Lo Bianco C; Bezard E; Fernagut PO
Hum Mol Genet; 2017 Jul; 26(14):2603-2615. PubMed ID: 28520872
[TBL] [Abstract][Full Text] [Related]
9. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
10. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
Paumier KL; Luk KC; Manfredsson FP; Kanaan NM; Lipton JW; Collier TJ; Steece-Collier K; Kemp CJ; Celano S; Schulz E; Sandoval IM; Fleming S; Dirr E; Polinski NK; Trojanowski JQ; Lee VM; Sortwell CE
Neurobiol Dis; 2015 Oct; 82():185-199. PubMed ID: 26093169
[TBL] [Abstract][Full Text] [Related]
11. Direct α-synuclein promoter transactivation by the tumor suppressor p53.
Duplan E; Giordano C; Checler F; Alves da Costa C
Mol Neurodegener; 2016 Feb; 11():13. PubMed ID: 26833254
[TBL] [Abstract][Full Text] [Related]
12. The new line of genetically modified mice with constitutive knockout of the gene alpha synuclein to study pathogenetic aspects of differential loss of dopaminergic neurons .
Tarasova TV; Ustyugov AA; Ninkina NN; Skvortsova VI
Patol Fiziol Eksp Ter; 2016; 60(3):4-9. PubMed ID: 29243900
[TBL] [Abstract][Full Text] [Related]
13. Brain infusion of α-synuclein oligomers induces motor and non-motor Parkinson's disease-like symptoms in mice.
Fortuna JTS; Gralle M; Beckman D; Neves FS; Diniz LP; Frost PS; Barros-Aragão F; Santos LE; Gonçalves RA; Romão L; Zamberlan DC; Soares FAA; Braga C; Foguel D; Gomes FCA; De Felice FG; Ferreira ST; Clarke JR; Figueiredo CP
Behav Brain Res; 2017 Aug; 333():150-160. PubMed ID: 28668282
[TBL] [Abstract][Full Text] [Related]
14. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
[TBL] [Abstract][Full Text] [Related]
15. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease.
Gorbatyuk OS; Li S; Sullivan LF; Chen W; Kondrikova G; Manfredsson FP; Mandel RJ; Muzyczka N
Proc Natl Acad Sci U S A; 2008 Jan; 105(2):763-8. PubMed ID: 18178617
[TBL] [Abstract][Full Text] [Related]
16. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
17. High Throughput Sequencing Identifies MicroRNAs Mediating α-Synuclein Toxicity by Targeting Neuroactive-Ligand Receptor Interaction Pathway in Early Stage of Drosophila Parkinson's Disease Model.
Kong Y; Liang X; Liu L; Zhang D; Wan C; Gan Z; Yuan L
PLoS One; 2015; 10(9):e0137432. PubMed ID: 26361355
[TBL] [Abstract][Full Text] [Related]
18. Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease.
Williams GP; Schonhoff AM; Jurkuvenaite A; Thome AD; Standaert DG; Harms AS
J Neuroinflammation; 2018 Aug; 15(1):244. PubMed ID: 30165873
[TBL] [Abstract][Full Text] [Related]
19. Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice.
Rabl R; Breitschaedel C; Flunkert S; Duller S; Amschl D; Neddens J; Niederkofler V; Rockenstein E; Masliah E; Roemer H; Hutter-Paier B
BMC Neurosci; 2017 Jan; 18(1):22. PubMed ID: 28143405
[TBL] [Abstract][Full Text] [Related]
20. Lack of pathogenic potential of peripheral α-synuclein aggregates from Parkinson's disease patients.
Recasens A; Carballo-Carbajal I; Parent A; Bové J; Gelpi E; Tolosa E; Vila M
Acta Neuropathol Commun; 2018 Feb; 6(1):8. PubMed ID: 29422109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]